
|Articles|April 27, 2018
Controversies in Urologic Cancer
How can you be sure you’ve selected the best approach for your patients with urologic cancer? As our experts debate developments like MRI fusion biopsy for PCa, HIFU for low-risk prostate cancer, and white light cystoscopy, learn how you can integrate these treatments into your practice.
Advertisement
Having trouble viewing?
Once you access the file, position your mouse over the top middle for a toolbar:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5







